{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/69a1a7a7811eb34558604616?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AI for Scientists, FDA Reverses Course, and Advances in Cancer Therapeutics","description":"<p>In the industry news section of this week’s episode, we kick things off with Tamarind Bio’s efforts to develop user-friendly artificial intelligence tools for science researchers. Then we examine the impact of the U.S. Food and Drug Administration’s reversal on its earlier refusal to review Moderna’s mRNA vaccine for the flu, discuss Gilead’s acquisition of Arcellx to expand its cancer therapy pipeline, and dive into Takeda’s investment in Vir Biotech’s prostate cancer candidate.&nbsp;Then on the research front, we get into the science behind new protein-like polymers engineered to target and degrade some of cancer’s most challenging driver proteins. And we discuss a potential control switch for CAR T cells that could make these immunotherapies much safer.</p><p>&nbsp;</p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Fay Lin, PhD, Uduak Thomas and Alex Philippidis for a discussion of the latest biotech and biopharma news.&nbsp;</p><p>&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>:&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/tamarind-bio-secures-13-6m-series-a-to-make-ai-more-accessible-for-biology/\" rel=\"noopener noreferrer\" target=\"_blank\">Tamarind Bio Secures $13.6M Series A to Make AI More Accessible for Biology</a></p><p>By Fay Lin, PhD, <em>GEN Edge</em>, February 24, 2026</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/infectious-diseases/stockwatch-fda-reversal-boosts-moderna-but-not-other-vaccine-companies/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: FDA Reversal Boosts Moderna, But Not Other Vaccine Companies</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, February 21, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/cancer/gilead-to-acquire-arcellx-for-7-8b-adding-anito-cel-to-cancer-pipeline/\" rel=\"noopener noreferrer\" target=\"_blank\">Gilead to Acquire Arcellx for $7.8B, Adding Anito-Cel to Cancer Pipeline</a></p><p>By Alex Philippidis, <em>GEN Edge</em>, February 23, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/cancer/astellas-vir-biotechnology-launch-up-to-1-7b-prostate-cancer-collaboration/\" rel=\"noopener noreferrer\" target=\"_blank\">Astellas, Vir Biotechnology Launch Up-to-$1.7B Prostate Cancer Collaboration</a></p><p>By Alex Philippidis, <em>GEN</em>, February 26, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/cancer/new-protein-like-polymers-target-degrade-undruggable-proteins-driving-cancer/\" rel=\"noopener noreferrer\" target=\"_blank\">New Protein-Like Polymers Target, Degrade “Undruggable” Proteins Driving Cancer</a></p><p><em>GEN</em>, February 11, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/topics/cancer/drug-controlled-car-t-cells-may-enable-safer-immunotherapy/\" rel=\"noopener noreferrer\" target=\"_blank\">Drug-Controlled CAR T Cells May Enable Safer Immunotherapy</a></p><p><em>GEN</em>, February 23, 2026</p><p><br></p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a>&nbsp;</p><p>Hosted by Corinna Singleman, PhD&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a>&nbsp;</p><p>Hosted by Jonathan D. Grinstein, PhD&nbsp;</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}